BRCA2 and breast carcinoma: A recent meta-analysis by Akdeniz and colleagues [181] computed the relative risk of contralateral breast cancer development as 2.68 (95% CI 1.69–3.65) for c.1100delC mutation carriers versus noncarriers (which was fully comparable with that in BRCA2 mutation carriers: RR = 2.75; 95% CI 1.77–4.29).